Clinical Geriatrics
Published: 2020-10-15

Elderly with COPD: comoborbitidies and systemic consequences

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy
aging COPD comorbidity adiponectin


Chronic obstructive pulmonary disease (COPD) represents a comple respiratory disorder characterized by persistent respiratory symptoms due to chronic airflow limitation caused by exposure to noxious particles/gases with an increased inflammatory response of the airways. COPD is common in older people, with an estimated prevalence of 10% in the US population aged > 75 years and is often accompanied by other concomitant chronic conditions that negatively impact prognosis and health status. The aim of this paper is to highlight the relationship between COPD and other comorbidities in elderly population. We focus our attention on the relationship existing between COPD and cardiovascular diseases, lung cancer, obstructive sleep apnoea syndrome, malnutrition/sarcopenia and osteoporosis with particular attention to adipokines, considering that adipose tissue plays a relevant role in the cross-talk between organs.


Chronic obstructive pulmonary disease (COPD) represents a complex respiratory disorder characterized by persistent respiratory symptoms due to chronic airflow limitation caused by exposure to noxious particles/gases with an increased inflammatory response of the airways 1,2.

COPD global prevalence is about 11.7% and is responsible for around 3 million deaths annually 3. Age is often listed as a risk factor for COPD. Chronic obstructive pulmonary disease (COPD) is common in older people, with an estimated prevalence of 10% in the US population aged > 75 years 4. It is unclear if aging leads to COPD or if age reflects the sum of cumulative exposures throughout life 5. COPD is often accompanied by other concomitant chronic conditions that negatively impact prognosis and health status 6,7. A large body of literature demonstrates that comorbidities are a widespread problem in COPD patients 8-11. A review of studies from different countries reports that 86 to 98% COPD patients have at least 1 other chronic disease with average number of comorbidities per individual ranging from 1.2 to 4.3 9. Furthermore, the prevalence of comorbidities was found especially high in patients with severe COPD 10. In addition, a recent meta-analysis highlights that the prevalence of comorbidities in COPD patients is significantly higher in comparison to non-COPD individuals 11. Some typical comorbidities of COPD are of particular importance for the elderly and require special attention because they are relevant for disease management in these patients 12. Chronic systemic inflammation state in COPD may have an impact on the natural history of other chronic conditions even if its role is not totally understood 13. Recent scientific interest has been focusing on biomolecular pathways implicated in cross-talk between organs and their potential in systemic consequences of COPD 14-18. In this context adipose tissue appears to retain a relevant role 19.

COPD is associated with the following systemic diseases 20:

  1. cardiovascular diseases: ischemic heart disease, cerebrovascular disease, peripheral artery disease, left and right heart failure, pulmonary hypertension, arrhythmias (atrial fibrillation and flutter), arterial hypertension;
  2. respiratory tract diseases: obstructive sleep apnea, pneumonia, lung fibrosis;
  3. metabolic diseases: metabolic syndrome, type II diabetes mellitus, dyslipidemia;
  4. haematological diseases/coagulopathies: secondary polycythemia, anaemia, venous thrombosis and pulmonary embolism;
  5. musculoskeletal diseases: muscle dysfunction, muscle wasting, osteoporosis;
  6. gastro-intestinal diseases: gastro-oesophageal reflux disease, peptic ulcer disease, liver cirrhosis;
  7. renal diseases: renal dysfunction;
  8. psychiatric diseases: depression, anxiety;
  9. cancers: lung, esophageal, pancreatic, breast, and all other cancers.

Comorbidities are inversely correlated with self-reported health status 9 and the presence of more than three comorbidities impacts quality of life more than lung function 21. Moreover, the risk of exacerbation and hospitalization is related to the number of comorbidities 22, as well as the risk of mortality 23 and total annual cost of the disease 24.

Polypharmacy, defined as the use of more than 5 or 10 pharmacological agents, is another key concept in the COPD management. In the general population it is associated with multimorbidity 25 and with an increased risk of adverse drug reactions (ADRs), especially in the elderly 26-28.

Exacerbation and infectious episodes influence the course of the disease resulting in increased symptom burden 29-31.

In conclusion, in order to achieve the goal of improved quality of life and survival, the correct management of COPD in elderly should include identification and treatment of all chronic associated conditions.

In this review we discuss the relationship between COPD and other comorbidities, in elderly population.


Cardiovascular diseases (CVD) are the most prevalent comorbidities in COPD elderly patients. Pulmonary hypertension, right ventricular dysfunction, arterial stiffness, systemic hypertension, left ventricular dysfunction, dysrhythmia, chronic heart failure and ischemic coronary disease have higher incidence and prevalence in patients suffering from COPD when compared with healthy population. This is not surprising because the two conditions share common risk factors, such as smoking, physical inactivity and ageing. Systemic inflammation and oxidative stress are centrally involved in the pathophysiology of both COPD and cardiovascular diseases promoting atherosclerosis 32. The viscoelastic properties of the arteries allow propagation of the pulse wave along vessel walls generated from left ventricular ejection. The speed of this wave is directly linked to arterial stiffness. Early studies demonstrated that arterial stiffness is an independent predictor of cardiovascular accidents in other chronic pathological conditions, such as diabetes, renal failure and systemic hypertension 33. In individuals suffering from COPD, in contrast to healthy age-matched controls, arterial stiffness has been shown to be increased, and correlates with the degree of airflow limitation. The mechanisms responsible for higher arterial stiffness in patients with COPD are largely unknown. The most plausible hypothesis is that, similar to that proposed for other chronic inflammatory condition, arterial stiffness is related to the state of chronic systemic inflammation that follows local (lung) inflammation as a consequence of “spill over” of the inflammatory process into the systemic circulation 34. Indeed, fibrinogen levels and C-reactive protein are higher in COPD patients than in control subjects 35,36. However, the possibility that systemic inflammation due to causative factors such as smoking exposure eventually affect the airways, thus leading to inflammatory changes that predispose to COPD, cannot be ruled out. An interesting hypothesis is that both impaired lung function and increased arterial stiffness in COPD are due to the increased susceptibility to degradation of connective tissue, as an expression of premature ageing triggered by smoking exposure. Elastolytic activity by means of metalloproteinases is enhanced in emphysema and atherosclerosis: firstly, elastin degradation leads to loss of alveolar attachments and emphysema; on the other hand, elastin degradation is associated with increased collagen and thicker arteries 37 in elderly. Hypoxia, commonly observed in advanced stages of COPD, is responsible for vasoconstriction of the pulmonary vascular bed and remodeling with myointimal hyperplasia causing, in turn, pulmonary hypertension and right ventricle hypertrophy and dilation 38. Wats et al investigated the relationship between lung function, heart size, heart dysfunction and the consequences for 6-min walking distance (6MWD) in patients with COPD in different stages. The results of the study have shown that static hyperinflation (inspiratory-to-total lung capacity ratio [IC/TLC], functional residual capacity, and residual volume) is better related to cardiac chamber sizes than airway obstruction or diffusion capacity. The authors demonstrated that COPD patients with an IC/TLC < or = 0.25 had a significantly impaired left ventricular diastolic filling pattern and a significantly impaired global ventricular function (expressed as Tei-index) compared with patients with an IC/TLC > 0.25 39. Despite a clear relationship between the above-mentioned illness, results of a study from Macchia and colleagues show that at least 20% of patients with COPD suffering from left ventricular dysfunction that affects survival, are misdiagnosed 40. For these reasons the definition of a clear protocol for diagnosis is important for management and follow up of CVD in COPD patients. André S et al. proposed a diagnostic algorithm for CVD evaluation in COPD, suggesting, in stable patients not experiencing an acute exacerbation, a baseline ECG and laboratory test such as Brain type Natriuretic Peptide (BNP) and N-terminal pro-BNP that are sensitive biomarkers of heart failure. Higher levels of BNP are associated with an increase of mortality risk. Dosing serum levels of c-reactive protein (CRP) seems to be useful also in evaluation of CVD; indeed, patients who present both moderate/severe obstruction and higher CRP serum levels have higher risk of ischemic heart disease. Echocardiogram is proposed only if needed after evaluation of symptoms and ECG 41. Treatment of CVD in COPD patients has changed significantly in the last decade. For a long time β-blockers were not prescribed in patients with COPD fearing that their use might be responsible for bronchoconstriction. Even after the release of new molecules with higher affinity for β1 adrenergic receptors and lower for β2 receptors, COPD was still considered by a lot of clinicians a good reason for choosing another type of medication even if less effective. Several observational studies evaluated safety and efficacy of standard dose of β blockers in COPD patients, showing that their use is related to a reduction in overall mortality, exacerbation rate and severity. Furthermore, recent studies have demonstrated that β blockers could represent the best treatment of hypertension in the COPD subgroup 42. ESC Guidelines suggest that for patients with heart failure and concurrent COPD metoprolol, bisoprolol or nebivolol should be preferred instead of carvedilol 43.


Recent achievements have changed the biological view about adipocytes functions. White adipose tissue is considered an endocrine source of biologically active substances with local and/or systemic action called adipokines 44. An inappropriate secretion of adipokines seems to participate in the pathogenesis of obesity-related diseases including endothelial dysfunction, inflammation and atherosclerosis 45. In particular, the intercorrelation between adipose tissue and lung has become clear; the involvement of leptin and adiponectin has been demonstrated in several lung diseases such as COPD, emphysema, asthma and cancer 46-49. In fact, through the secretion of adipokines, adipose tissue participates in the regulation of several patho-physiological processes in many organs and tissues. Among the adipokines, adiponectin and leptin are the two most relevant. The biological function of adipokines in lung diseases seems to be mainly related to the inflammatory process 50. In fact, with specific regard to COPD, a low-grade inflammatory state has been demonstrated. Adiponectin is one of the most abundant circulating adipocytokines, accounting for the 0.01% of total serum protein. Adiponectin is involved in a wide variety of physiological processes including energy metabolism, inflammation, and vascular physiology. These effects are mediated by two atypical widely expressed seven-transmembrane receptors, AdipoR1 and AdipoR2. Adiponectin has beneficial effects in cardiovascular systems and blood vessels protecting these tissues through the inhibition of pro-inflammatory and hypertrophic responses and stimulation of endothelial cell responses. In addition, growing evidence suggests that adiponectin also exerts a crucial role on vascular endothelium maintaining vascular homoeostasis and being protective against vascular dysfunctions 51,52. Altogether these findings support the anti-inflammatory role of adiponectin in COPD patients. Previously, we reported higher adiponectin levels in COPD compared to healthy subjects 53. Furthermore, since adiponectin circulates as three different isoforms (low molecular weight-LMW, medium molecular weight-MMW and high molecular weight-HMW), we investigated the oligomerization state of serum adiponectin. Interestingly, we found for the first time that the adiponectin oligomerization state is altered in COPD; particularly, we observed that the higher levels of adiponectin are associated with a significant and specific increase of HMW, representing the most biologically active forms. In addition, we demonstrated the presence of AdipoR1 and AdipoR2 with a lower expression of AdipoR2 compared to AdipoR1. Moreover, we demonstrated the expression of both AdipoR1 and 2 in lung tissues from COPD with non-small cell lung cancer (NSCLC) with a lower expression of AdipoR2 compared to AdipoR1. The important role of adiponectin in patho-physiological conditions of lung is also supported by the modulation of AdipoRs with the down regulation of AdipoR2. The low expression of AdipoR2 may indicate a specific role of this receptor, mainly implicated in adiponectin effects on inflammation and oxidative stress. In addition to the above-mentioned epidemiologic studies, in vitro studies have demonstrated that adiponectin has protective effects against inflammation and the aberrant growth of cancer cells 54,55. In particular, in a model of lung inflammation, adiponectin is able to reduce damage induced by pro-inflammatory cytokines 56. Regarding leptin, many studies have reported that leptin provides a link between obesity and lung diseases. It is well known that leptin is a pro-inflammatory mediator in COPD disease. In fact, an increase of leptin in human sera leads to impaired immune responses and facilitates the infection resulting in increased pneumonia severity 57. Furthermore, the upregulation of migration, inhibition of apoptosis, and increased proliferation are also found in leptin-stimulated airway epithelial cells 58. In both in vivo and in vitro studies, leptin promoted the expression of the cPLA2α gene in lung alveolar type II cells via MAPK and NF-κB-activated coactivator p300 59. In the lung system, the increased leptin induced cPLA2α/COX-2 expression and leukocyte infiltration via the NADPH oxidase-dependent production of ROS. These evidences confirm the inflammatory effect of leptin in the lung and in particular in COPD, and suggest that leptin plays a central role in the pathogenesis of COPD in obese subjects.


COPD and lung cancer are closely related, based on shared main risk factors. Ongoing research is exploring the linking mechanisms, such as premature lung aging, genetic predispositions, common pathogenic factors or intracellular pathways or epigenetics factors 60.

Certainly, lung cancer is five times more common in smokers with COPD than in those with normal lung function 61,62 and COPD is an independent risk factor for lung carcinoma, mostly for squamous cell carcinoma 63. Despite the advances in early identification and in the therapeutic management of both COPD and lung cancer the underlying networking mechanisms are far from being well established resulting in poor prognosis 64-69.

Many epidemiological studies have showed that emphysema and air flow obstruction are both involved as risk factors for lung cancer incidence and death, but their relative roles have not been fully clarified. Firstly, both chronic respiratory obstructive diseases and lung cancer are common in the aging lung 70.

The risk of developing cancer increases with age and is higher in COPD patients over 40 years old 71,72. Lung function decline with age is faster and premature in COPD due to oxidative stress and telomere shortening. Free radicals, such as RNOS, are exogenous (cigarettes) and also endogenous, generated by mitochondrial respiration. This is typically dysfunctional in cancer 73. All these mechanisms lead to DNA damage, lipid peroxidation and amino acid oxidation. These evidences validate the free radical hypothesis of aging, which suggests RNOS accumulation determines DNA damage and cell transformation to malignant ones if not correctly repaired (point mutations, single and double stand breaks, DNA-crosslinking) 74.

RNOS can also inactivate tumor suppressors and apoptosis factors, allowing tumor growth to continue. RNOS are also intracellular signals activating, directly or indirectly, inflammatory and proliferative pathways (such as ROS receptor/proto-oncogene ROS1- and PI3K-mTOR pathway, c-Jun N-terminal kinases JNK, dependent mitogen activate protein kinase (MAPK), NF-Kb pathway), upregulating immune and inflammatory genes expression. Furthermore, NO stimulates tumor growth activating vascular endothelial growth factor (VEGF) 75.

Some studies have showed the correlation between short telomere length and both lung cancer and COPD 76. Telomeres are repetitive nucleotide sequences that protect the chromosome against the shortening caused by DNA replication. When telomeres arrive at the Hayflick limit and become too short, involving the tumor suppressor proteins p53 and Retinoblastoma protein (Rb), the cell is not able to divide further and goes towards senescence. These mechanisms prevent excessive replication and the risk of generating neoplasms. However, some cells can inactivate Rb and p53 signaling pathways, giving life to a perennial clone that preserve telomere length despite cells divisions. Telomere shortening is also accelerated by smoking, leading more rapidly to replicative senescence, inflammation and emphysema, causing COPD or generating a cancer clone cell 77. There are also evidences of a familial predisposition to lung cancer and COPD. Some regions in chromosome 6 seem to be involved: CHRNA3, CHRNA5 SNPs (15q), HHIP, FAM13A and HTR4 78. The rs7326277TT genotype in VEGFR1 is a locus connected with inflammation, epithelial to mesenchymal transition and tumor growth. Also epigenetic changes can be involved in the development of COPD and cancer. Hypermethylazion of tumor suppressor or gene promoters is common in lung cancer and also hypomethylation of immunomodulatory genes 79. Methylation of the 5’ position of a cytosine residue of tumor suppressor genes (APC, CDKN2, BRCA1, RB, mdm2) induces proliferation. A new prospective will be cluster DNA methylation patterns, corresponding to 3 lung cancer clusters and different carcinogenetic factors 80,81.

The recent EWAS study has examined the links between gene methylation in COPD and lung cancer, and the result was that methylation and repression of CCDC37 and MAP1B is associated with COPD and lung cancer 82.

Cigarette smoke reduces the activity of HDAC2 at protein and mRNA level, inducing a lower inactivation of inflammatory genes. The role of mRNAs and miRNAs is not totally clear. MiR-1 seems to be linked to cigarette smoking-related diseases and is downregulated in skeletal muscle 83. Other miRNA involved are miR-21 and miR-146a, this one is particular because may downregulate inflammation and proliferation 84. Considering all the common elements between COPD and lung cancer, chronic inflammation in COPD could serve as a bridge for the development of lung cancer. The inflammatory context influences the cancer microenvironment and cytokines signaling which may 85-87 interfere with therapy including Immunecheck points inhibitors 88,89. The overexpression of NF-kB in chronic inflammation is the first mediator of inflammation-induced carcinogenesis. It induces IL-1, IL-6, IL-8, TNFα and also many factors of the cell cycle, such as cyclines D1, D2, D3, E1 and various CDKs, and suppresses p53. Cigarette smoke induces an aberrant expression of growth factors (as EGF) which increase the rate of cell division and repair lung damage. This leads to epithelial-mesenchymal transition (EMT), a process linked to both cancer and COPD. COPD patients live in a hypoxic condition (air trapping, emphysema, airflow flow obstruction) and this is a trigger to activate hypoxia inducible factor (HIF) 1-α. This factor is induced also by the cancer hypoxic environment, regulating glycolisis, telomerase activation, inhibition of apoptosis and cell differentiation. The emphysematous microenvironment could also encourage lung cancer growth. The alveolar capillary destruction and poor vascularization, typical of emphysematous areas, could lead to expression of genes of hypoxia-inducible factor-1α or could induce to mutation in genes such as TP53 and CDK2N2A. Therefore, the cells may avoid apoptosis and become able to transform into a cancerous focus. With the diffusion of computed tomography (CT), it is now possible to detect the severity of emphysema 90. The method for evaluating emphysema is fundamental and it appears that visual detection has a more important clinical correlation despite the automated computer analysis. The cancer results correlated only to visually-detected emphysema 91. Contrary to common belief, several studies have noticed a possible inverse relationship between incidence of lung cancer and the severity of air flow obstruction. Older age, low BMI, DLCO < 80% predicted and GOLD Stages I and II (even small differences in FEV1 % predicted) seem to be the real independent risk factors for the development of lung cancer 92. It is hypothesized that smokers, who develop milder disease, have a dysfunctional immune system enabling the cancer progression. Instead patients with severe COPD have a more aggressive immune system that can block cancer growth. It appears that CD4+ T-cell Th1 and Th17, CD8+ T-cell increase with the disease progression 93. Furthermore CD8+ cells create expression of the inhibitory receptors PD1, TIM3 and PDL1 and this may explain why patients with COPD Lung cancer display longer survival with anti-PD1 antibodies 94.

Smokers with mild and moderate air flow obstruction, DLCO < 80% predicted or CT detected emphysema, have a particular risk for development of lung cancer and could represent the right target for a screening program. Lung functional parameters are also crucial in the pre-surgical evaluation of patients undergoing lung resection for lung cancer 95,96. The United States Preventive Services Task Force (USPSTF) recommends low-dose CT since 2014 97. A novel score to predict lung cancer risk for patients with COPD is the COPD-LUCSS, characterized by four parameters: age > 60, BMI < 25 kg/m2, pack-years > 60, presence of radiological emphysema; with a total range from 0 to 10 points. Low-risk patients (scores 0-6), high risk 7-10,98. Available data show that lung cancer screening in COPD patients, using proper scores, may improve early diagnosis of lung cancer, reducing late stage diagnosis 99. Regarding the impact on mortality, screening mild and moderate COPD significantly reduces the incidence; therefore, active screening is justified in these patients 100. However, the benefits of a screening program are perhaps not so relevant because there are other concomitant causes of death caused by COPD 101.


The relationship between obstructive sleep apnoea syndrome (OSAS) and COPD has recently been a matter of great interest.

This relationship is complex, with common risk factors and hypothesized mutual causal links. Continuous positive airways pressure (CPAP) is the gold standard for the treatment of OSAS and plays a major role in the therapeutic management of the COPD-OSAS overlap syndrome. OSAS is characterized by recurrent episodes of partial or complete upper airways collapse with various respiratory events such as flow limitations, snoring, obstructive hypopneas and apnoeas. The upper airways patency – influenced by the activity of pharyngeal constrictor and dilator muscles – is therefore critical in the pathogenesis of the OSAS patients’ nocturnal events. The nocturnal respiratory events and their cyclic recurrence cause oxyhaemoglobin desaturations with neurophysiological consequences like sleep fragmentation and morning sleepiness 102. Long term negative effects on cardiac and cerebrovascular homeostasis are of great importance too. They are the reason why OSAS patients have a higher risk of arterial hypertension, arrhythmias, myocardial ischaemia and stroke 103. In COPD patients sleep is frequently shorter and of poor quality. The cause has been traced back to the COPD itself and to pharmacologic polytherapy. During COPD patients’ sleep, the ventilation physiological reduction is enhanced with a change in the ventilatory pattern and in the blood gases levels, configuring the typical pattern of the NOD (nocturnal oxygen desaturation) 104. The suspected causative mechanisms are: reduced chemosensitivity of the respiratory nuclei, weakened contraction of the respiratory muscles, increased peripheral resistance, reduced residual functional capacity (RFC) enhanced by the supine position.The patients already hypoxemic awake, like those hypercapnic awake, show higher levels of nocturnal oxygen desaturation. Such events of oxygen desaturation are more intense during stage 3 of NREM sleep and during REM sleep 105. For many years now the relationship between OSA and COPD is acknowledged under the title of Overlap Syndrome. About 15% of COPD patients suffer from concurrent OSA. Such patients show lower levels of nocturnal haemoglobin saturation and a higher risk of chronic cor pulmonale and arterial hypertension. Overlap syndrome patients present hypercapnia earlier when compared with COPD patients and analogue functional impairment without OSA. The therapeutic approach to the overlap syndrome consists of simultaneous treatment of both pathologies. Machado et al. observational study performed on patients suffering from COPD and OSA demonstrated a longer survival in the patients accepting CPAP as OSA treatment 106. Marin et al. proved that the Overlap Syndrome patients had a higher risk of severe COPD exacerbation and hospitalization 107. The discontinuation of a smoking habit and good inhaled therapy compliance are mandatory for the success of treatment. Oxygen therapy alone is not recommended in patients with COPD and OSAS especially in those with awake hypercapnia but can be of help in the resolution of the residual desaturation after correction of the apnoeas 108. CPAP remains the gold standard for treatment of OSA patients. BIPAP (biphasic positive airway pressure, BIPAP) is useful in patients with a low compliance to CPAP and in those with hypercapnia 109.


COPD is known to negatively affect the elder patients’ nutritional status, being able to produce specific morbid conditions as malnutrition and sarcopenia whose assessment is relevant for a correct management of the pathology.

Malnutrition can be diagnosed referring to the latest and widely used criteria proposed by the European Society for Clinical Nutrition and Metabolism (ESPEN) in 2015. According to the ESPEN consensus, patients are classified as malnourished when they have a body mass index (BMI) < 18.5 kg/m2 or between 18.5 and 22 kg/m2, combined with a free fat mass index (FFMI) < 17 kg/m2 for men and < 15 kg/m2 for females. The simultaneous presence of elevated serum CRP concentrations (CRP ≥ 5 mg/dL), and/or reduced serum concentrations of albumin (albumin < 3.5 g/dL), combined with malnutrition, is a criterion for the diagnosis of cachexia or disease-related malnutrition with inflammation 110.

Sarcopenia is another nutritional phenotype to consider in the evaluation of COPD patients. Broadly accepted diagnostic criteria for sarcopenia have been developed by the European Working Group of Sarcopenia in Older People (EWGSOP), who have proposed an algorithm based on loss of skeletal muscle mass (SM) plus reduced strength and/or performance 111.

Low muscle mass can be evaluated performing a multifrequency BIA (body impedance assessment) in standardized conditions (i.e. ambient temperature between 23 and 25 °C, fast > 3 h, empty bladder, supine position for at least 10 min before starting the measurement). The skeletal muscle mass index (SMI) cut-off values are ≤ 8.50 kg/m2 for men and ≤ 5.75 kg/m2 for women 112.

Low muscle strength can be assessed by handgrip strength (HGS), a proxy index of overall muscle strength, measured with a digital hand-held dynamometer and expressed in kg. Patients are asked to perform a maximum voluntary isometric contraction of finger flexor muscles 113.

Physical performance is measurable by a 4-m gait speed test, as described by Kon et al. 114. Patients are asked to walk down a 4 m flat, unobstructed course at their usual speed. Low walking speed is defined as walking slower than 0.8 m/s.

In the literature the prevalence of COPD-related malnutrition is quite variable due not only to the characteristics of patients (stages of the disease, exacerbations, etc.), but also to the use of different diagnostic approaches. De Blasio et al., using the diagnostic criteria for malnutrition proposed by the 2016 ESPEN consensus, reported an average prevalence of 19.8% 115-118 that was higher in the more advanced stages of disease, as already reported in previous papers using other diagnostic approaches 119. The prevalence of sarcopenia, referring to EWGSOP criteria is reported to vary between the 14.5 and 25% 120. Several factors have been shown to participate in the multifactorial aetiology of COPD-related malnutrition and sarcopenia including systemic inflammation, a well-known condition associated with COPD 121. A recent study by Byun et al. 122 demonstrated, performing a multivariate analysis, that higher hsTNFa was a significant determinant for the presence of sarcopenia. In the same study, muscle strength assessed by HGS and muscle mass (MM) measured by skeletal muscle mass index (SMMI) showed significant correlation with levels of IL-6 and hsTNFα. Such results are noteworthy since all patients had stable, not exacerbated COPD. The notion that systemic inflammation contributes to skeletal muscle wasting in COPD patients is supported by the fact that many proinflammatory cytokines can adversely influence the skeletal muscle mass through the activation of muscle proteolysis and the inhibition of protein synthesis in elderly 123. Experimental studies have shown that inflammatory markers, such as increased blood levels of TNF-α, promote muscle wasting by enhancing the activity of the ubiquitin proteasome pathway or by inducing apoptosis 124. Other aetiological factors of COPD-related malnutrition and sarcopenia are: chronic hypoxia inducing a reduction in muscle mass probably as a result of the interaction of several molecular mediators such as inflammation, hypoxia inducible factor-1 signaling pathway, oxidative stress, and reduced oxidative enzyme capacity and capillary numbers; hypercapnia, which may worsen during exacerbations, negatively affecting the muscle mass through acidosis as it enhances ubiquitin-proteasome proteolytic system activity and/or through a reduction in protein anabolism; cigarette smoking; drugs, especially systemic corticosteroids; physical inactivity 125,126. The evaluation of the nutritional status should be of primary importance in the management of COPD considering the following evidences: a low free fat mass index strongly correlates with the mortality in normal-weight COPD patients; sarcopenia is associated with loss of mobility, falls, osteoporosis, poor quality of life (QOL) due to fractures, hospitalization, and death 127.

Various therapeutic approaches have been proposed regarding COPD-related malnutrition and sarcopenia. Pulmonary rehabilitation (PR) in elderly patients with COPD has already been proven beneficial with high-quality evidence. PR is a multidisciplinary integrated treatment program that contains exercise, education, behaviour change, and nutritional therapy. Exercise refers to a planned and repetitive activity for a specific purpose over a certain period of time, with a definition different from that of physical activity. Exercise is also one of the most effective ways to improve sarcopenia. The EWGSOP noted that exercise with a primary goal of improving physical performance, strength and muscle mass is fundamental for sarcopenia treatment 128. Exercise in sarcopenia is largely composed of resistance exercise, aerobic exercise, and balance and flexibility exercises. Intensive resistance training by elderly patients effectively increases muscle function and mass. Nutritional support plays a key role too. Significant improvements in mid-arm muscle circumference, FFMI, 6MWT, respiratory muscle strength, and overall health-related QOL have been reported with nutritional supplementation in malnourished patients with COPD 129. The PROT-AGE study group recommended a protein supply of 1.0 to 1.2 g/kg for healthy elderly people and 1.2 to 1.5 g/kg for elderly people with chronic or acute disease 130. Some medicines and supplements currently available in clinical practice may be useful for patients with sarcopenia and COPD. Vitamin D is thought to play an important role in muscle metabolism, and it was recently reported that vitamin D plays a role in skeletal muscle mass and muscle strength. When vitamin D was deficient, atrophy of type II muscle fiber was confirmed. It was also reported that muscle performance was improved when the 25-hydroxy-vitamin D concentration was more than 60 nmol/L 131. Beta-hydroxy-β-methylbutyrate (HMB) is a metabolite of leucine and is often used as a nutritional supplement during muscle training. HMB increases protein synthesis through protective and anti-catabolic effects. It also stabilizes muscle cell membranes and weakens proteolytic pathways. This process can contribute to a reduction of sarcopenia. In chronic diseases including COPD, HMB was effective in preventing muscle loss, and it was reported that the usual dose of 3 g/ day HMB was effective with no definite side effects 132,133. Selective Androgen Receptor Modulator has recently been shown to be effective in the prevention and treatment of muscle wasting in clinical trials in cancer patients 134, and clinical trials are underway for other diseases such as COPD.


Elderly affected by COPD experience an increased risk of developing osteoporosis. The prevalence of osteoporosis in COPD is between 4 and 59%, depending on the diagnostic method used, the population studied, and the severity of underlying respiratory disease. A recent literature survey performed in COPD patients by Graat-Verboom and colleagues showed that a number of risk factors for osteoporosis can be identified, including low body mass, disease severity, use of corticosteroids, age and female gender 135. The presence of emphysema is a relevant factor, often associated with lower BMI and reduced BMD, and may represent a clinical phenotype at high risk of osteoporosis 136. Another central item in patients affected by COPD is the use of systemic GCSs which play a major role in increasing bone fracture incidence and have deleterious effect on BMD. A meta-analysis made by van Staa et al. 137 showed a strong inverse correlation between bone density and total cumulative dose of GCSs. A significant correlation was also found between the daily dose of GCSs and the risk of fractures, even with low oral doses of Prednisone as 2.5 to 5 mg. In addition to this, there are several studies that demonstrated how patients receiving oral GCSs are more likely to develop one or more vertebral fractures 138. On the other hand, the effects of inhaled corticosteroids (ICSs) on bone loss and fracture risk are less clear. Several studies reported mild effect of high doses of ICSs on bone turnover 139, moreover, a recent sub-analysis of TORCH study conducted on 658 patients revealed no significant effect of ICSs on BMD over the course of 3 years 140. On the basis of this, the treatment of osteoporosis in patients affected by COPD aims to reduce the risk of fracture and this goal can be achieved with pharmacological and non-pharmacological intervention (such as smoking cessation and physical activity). Pharmacological interventions consist of calcium and vitamin D supplementation and anti-resorptive therapy. Tang et al. in 2007, performed a systematic review to evaluate the effects of Calcium alone or in combination with vitamin D on osteoporotic fractures and BMD in adults aged 50 years or older, stating that combination therapy is best for fracture prevention when Vitamin D alone is ineffective in preventing fractures 141. Other drugs commonly used for the prevention and treatment of osteoporosis are bisphosphonates; several studies confirm their protective effect on bones, but few studies have specifically addressed the effect of antiresorptive agents in COPD. A randomized controlled trial performed by Smith et al demonstrated a significant improvement in lumbar spine BMD through daily intake of alendronate 142.


COPD is a very heterogeneous condition, common in older people. Whether aging leads to COPD or age itself reflects cumulative exposures throughout life leading to COPD remains matter of debate. Concomitant chronic conditions are relevant and negatively impact prognosis and health status. The role of ageing on development of comorbidities in COPD is increasingly recognized and the number of comorbidities is associated to the risk of exacerbation, hospitalization and mortality in COPD. Systemic inflammation affects natural history of COPD and is implicated in concomitant chronic conditions such as cardiac failure, osteoporosis, diabetes and peripheral artery diseases. Bio-molecular pathways implicated in cross-talk between organs and their potential in systemic consequences of COPD are under investigations. Growing scientific interest has been recently focused on Adipose tissue that appears to exert a relevant role.

As COPD comorbidities in elderly are complex a multidisciplinary approach to provide a comprehensive management to a multifaceted disease is required.

Figures and tables

Figure 1.Chronic obstructive pulmonary disease and main comorbidites in elderly patients.


  1. GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2017 REPORT).Publisher Full Text
  2. Mazzarella G, Lucariello A, Bianco A. Exposure to submicron particles (PM1.0) from diesel exhaust and pollen allergens of human lung epithelial cells induces morphological changes of mitochondria tonifilaments and rough endoplasmic reticulum. In Vivo. 2014; 28:557-61.
  3. Adeloye D, Chua S, Lee C. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015; 5:020415. DOI
  4. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. NCHS Data Brief. 2011; 63:1-8.
  5. Paolisso G. COPD in elderly patients. Journal of Gerontology and Geriatrics. 2016; 64:117-8.
  6. Libertini G, Corbi G, Cellurale M. Age-related dysfunctions: evidence and relationship with some risk factors and protective drugs. Biochemistry (Mosc). 2019; 84:1442-50.
  7. Vestbo J, Hurd SS, Agusti AG. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD Executive summary. Am J Respir Crit Care Med. 2013; 187:347-65.
  8. Noteboom B, Jenkins S, Maiorana A. Comorbidities and medication burden in patients with chronic obstructive pulmonary disease attending pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2014; 34:75-9.
  9. Putcha N, Puhan MA, Hansel NN. Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008. COPD. 2013; 10:324-32.
  10. Testa G, Cacciatore F, Bianco A. Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure. Aging Clin Exp Res. 2017; 29:1157-64.
  11. Yin HL, Yin SQ, Lin QY. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine. 2017; 96:e6836. DOI
  12. Pedone C. Comorbidities of COPD as a function of age: evidence and practical recommendations. Journal of Gerontology and Geriatrics. 2016; 64:126-30.
  13. Divo M, Cote C, de Torres J. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186:155-61.
  14. Conti V, Corbi G, Manzo V. Sirtuin 1 and aging theory for chronic obstructive pulmonary disease. Anal Cell Pathol (Amst). 2015; 2015:897327. DOI
  15. Conti V, Corbi G, Manzo V. SIRT1 activity in peripheral blood mononuclear cells correlates with altered lung function in patients with chronic obstructive pulmonary disease. Oxid Med Cell Longev. 2018; 2018:9391261. DOI
  16. Flora M, Perrotta F, Nicolai A. Staphylococcus aureus in chronic airway diseases: an overview. Respir Med. 2019; 155:66-71. DOI
  17. Maniscalco M, Bianco A, Mazzarella G. Recent advances on nitric oxide in the upper airways. Curr Med Chem. 2016; 23:2736-45.
  18. Maniscalco M, Vitale C, Vatrella A. Fractional exhaled nitric oxide-measuring devices: technology update. Med Devices (Auckl). 2016; 9:151-60.
  19. Faner R, Cruz T, López-Giraldo A. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J. 2014; 44:775-88.
  20. Decramer M, Rennard S, Troosters T. COPD as a lung disease with systemic consequences–clinical impact, mechanisms, and potential for early intervention. COPD. 2008; 5:235-56.
  21. Van Manen JG, Bindels PJ, Dekker EW. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med. 2001; 95:496-504.
  22. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60:925-31.
  23. Miller J, Edwards LD, Agustí A. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107:1376-84.
  24. Huber MB, Wacker ME, Vogelmeier CF. Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS One. 2015; 10:e0123292. DOI
  25. Corsonello A, Pedone C, Corica F. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007; 3:197-203.
  26. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007; 30:911-8.
  27. Corbi G, Gambassi G, Pagano G. Impact of an innovative educational strategy on medication appropriate use and length of stay in elderly patients. Medicine (Baltimore). 2015; 94:e918.
  28. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5:691-706.
  29. Giannattasio A, Brunese L, Ripabelli G. Coinfections with influenza virus and atypical bacteria: implications for severe outcomes?. Clin Respir J. 2018; 12:366-7. DOI
  30. Bianco A, Parrella R, Esposito V. Severe A(H1N1)-associated pneumonia sequential to clamidophila pneumoniae infection in healthy subject. In Vivo. 2011; 25:825-8.
  31. Bianco A, Mazzarella G, Rocco D. FDG/PET uptake in asymptomatic multilobar Chlamydia pneumoniae pneumonia. Med Sci Monit. 2010; 16:CS67-70.
  32. Corbi G, Bianco A, Turchiarelli V. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on sirtuins. Int J Mol Sci. 2013; 14:12696-713. DOI
  33. Boutouyrie P, Tropeano AI, Asmar R. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002; 39:10-15.
  34. Gan WQ, Man SF, Senthilselvan A. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59:574-80.
  35. Dahl M, Tybjaerg-Hansen A, Vestbo J. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164:1008-11.
  36. Pinto-Plata VM, Müllerova H, Toso JF. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61:23-8.
  37. Costanzo L, Pedone C, Battistoni F. Relationship between FEV1 and arterial stiffness in elderly people with chronic obstructive pulmonary disease. Aging Clin Exp Res. 2017; 29:157-64.
  38. Watz H, Waschki B, Meyer T. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010; 138:32-8. DOI
  39. Criner GJ. COPD and the heart: when less lung means more heart. Chest. 2010; 138:6-8. DOI
  40. Macchia A, Rodriguez Moncalvo JJ, Kleinert M. Unrecognised ventricular dysfunction in COPD. Europ Resp J. 2012; 39:51-8.
  41. André S, Conde B, Fragoso E, GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and Cardiovascular Disease. Pulmonology. 2019; 25:168-76. DOI
  42. Vanfleteren L, Spruit M, Wouters F. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016; 4:911-24.
  43. Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of. Eur Heart J. 2016; 37:2129-200.
  44. Nigro E, Scudiero O, Monaco ML. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014; 2014:658913.
  45. Di Zazzo E, Polito R, Bartollino S. Adiponectin as link factor between adipose tissue and cancer. Int J Mol Sci. 2019; 20:pii: E839. DOI
  46. Nigro E, Daniele A, Scudiero O. Adiponectin in asthma: implications for phenotyping. Curr Protein Pept Sci. 2015; 16:182-7.
  47. Bianco A, Mazzarella G, Turchiarelli V. Adiponectin: an attractive marker for metabolic disorders in Chronic Obstructive Pulmonary Disease (COPD). Nutrients. 2013; 5:4115-25. DOI
  48. Maio S, Baldacci S, Simoni M, ARGA Study Group. Impact of asthma and comorbid allergic rhinitis on quality of life and control in patients of Italian general practitioners. J Asthma. 2012; 49:854-61.
  49. Baldacci S, Maio S, Simoni M, ARGA study group. The ARGA study with general practitioners: impact of medical education on asthma/rhinitis management. Respir Med. 2012; 106:777-85. DOI
  50. Perrotta F, Nigro E, Mollica M. Pulmonary hypertension and obesity: focus on adiponectin. Int J Mol Sci. 2019; 20:912.
  51. Bianco A, Nigro E, Monaco ML. The burden of obesity in asthma and COPD: role of adiponectin. Pulm Pharmacol Ther. 2017; 43:20-5.
  52. Corbi G, Polito R, Monaco ML. Adiponectin expression and genotypes in italian people with severe obesity undergone a hypocaloric diet and physical exercise program. Nutrients. 2019; 11:pii: E2195. DOI
  53. Daniele A, De Rosa A, Nigro E. Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2012; 44:563-9.
  54. Nigro E, Stiuso P, Matera MG. The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement. Pulm Pharmacol Ther. 2019; 55:25-30.
  55. Illiano M, Nigro E, Sapio L. Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells. Pulm Pharmacol Ther. 2017; 45:114-20.
  56. Nigro E, Scudiero O, Sarnataro D. Adiponectin affects lung epithelial A549 cell viability counteracting TNFα and IL-1ß toxicity through AdipoR1. Int J Biochem Cell Biol. 2013; 45:1145-53.
  57. Ubags ND, Stapleton RD, Vernooy JH. Hyperleptinemia is associated with impaired pulmonary host defense. JCI Insight. 2016; 1:pii:e82101.
  58. Suzukawa M, Koketsu R, Baba S. Leptin enhances ICAM-1 expression, induces migration and cytokine synthesis, and prolongs survival of human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2015; 309:801-11.
  59. Hsu PS, Wu CS, Chang JF. Leptin promotes cPLA(2) gene expression through activation of the MAPK/NF-kappaB/p300 cascade. Int J Mol Sci. 2015; 16:27640-58.
  60. Barnes PJ, Adcock IM. Chronic obstructive pulmonary disease and lung cancer: a lethal association. Am J Respir Crit Care Med. 2011; 184:866-7. DOI
  61. Young RP, Hopkins RJ. Link between COPD and lung cancer. Respir Med. 2010; 104:758-9. DOI
  62. Young RP, Hopkins RJ, Duan F. Airflow limitation and histology shift in the national lung screening trial. The NLST-ACRIN Cohort Substudy. Am J Respir Crit Care Med. 2015; 192:1060-7.
  63. Papi A, Casoni G, Caramori G. COPD increases the risk of squamous histological subtype in smokers who develop non -small cell lung carcionoma. Thorax. 2004; 59:679-81.
  64. Pilyugin M, Descloux P, André PA. BARD1 serum autoantibodies for the detection of lung cancer. PLoS One. 2017; 12:e0182356. DOI
  65. Zhang YQ, Bianco A, Malkinson AM. BARD1: an independent predictor of survival in non-small cell lung cancer. Int J Cancer. 2012; 131:83-94. DOI
  66. Rinaldi L, Milione S, Fascione MC. Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: a multicentre prospective study. Respirology. 2019. DOI
  67. Perrotta F, Khiroya R, Russell P. Diagnosis of combined adenocarcinoma small cell lung cancer by endobronchial ultrasound transbronchial needle aspiration. J Bronchology Interv Pulmonol. 2019; 26:e20-e2. DOI
  68. Fiorelli A, Perrotta F, Mollica M. Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report. J Cardiothorac Surg. 2019; 14:50. DOI
  69. Cattaneo F, Guerra G, Parisi M. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res. 2015; 35:2769-74.
  70. Mollica M, Salvi R, Paoli G. Lung cancer management: challenges in elderly patients. Journal of Gerontology and Geriatrics. 2019; 67:132-40.
  71. Longobardi L, Di Giorgio A, Perrotta F. Bronchial asthma in the elderly patient. Journal of Gerontology and Geriatrics. 2016; 64:55-65.
  72. Kamo K, Katanoda K, Matsuda T. Lifetime and age-conditionl probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol. 2008; 38:571-6. DOI
  73. Caramori G, Adcock IM, Casolari P. Unbalanced oxidant-induced DNA damage and repair in COPD: a link toward lung cancer. Thorax. 2011; 66:521-7. DOI
  74. Kryston TB, Georgiev AB, Pissis P. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011; 711:193-201. DOI
  75. Kobliakov VA. Mechanisms of tumor promotion by reactive oxygen species. Biochemistry (Mosc). 2010; 75:675-85.
  76. Hosgood HD, Cawthon R, He X. Genetic variation in telomere maintenance genes, telomere lenght, and lung cancer susceptibility. Lung Cancer. 2009; 66:157-61. DOI
  77. Amsellem V, Gary-Bobo G, Marcos E. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 184:1358-66. DOI
  78. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructibìve pulmonary disease. Am J Respir Crit Care Med. 2006; 173:16-22.
  79. Qiu W, Baccarelli A, Carey VJ. Variable, Methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med. 2012; 185:373-81. DOI
  80. Sato T, Eri A, Takashi K. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue:its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer. 2014; 135:319-34.
  81. Nigro E, Imperlini E, Scudiero O. Differentially expressed and activated proteins associated with non small cell lung cancer tissues. Respir Res. 2015; 16:74. DOI
  82. Tessema M, Yingling CM, Picchi MA. Epigenetic repression of CCDC37 and MAP1B links chronic obstructive pulmonary disease to lung cancer. J Thorac Oncol. 2015; 10:1181-8.
  83. Leidinger P, Keller A, Borries A. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011; 74:41-7. DOI
  84. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12:861-74. DOI
  85. Bianco A, Perrotta F, Barra G. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci. 2019; 20:4931.
  86. Bianco A, Malapelle U, Rocco D. Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharmacol. 2018; 40:46-50.
  87. Perrotta F, Rocco D, Vitiello F. Immune checkpoint blockade for advanced NSCLC: a new landscape for elderly patients. Int J Mol Sci. 2019; 20:2258.
  88. Bianco A, Campbell SFM. Atezolizumab plus platinum-based regimen and bevacizumab: Is it time to consider immunotherapy in a concurrent approach for lung cancer?. Transl Cancer Res. 2018; 8:S103-5. DOI
  89. Fiorelli A, Vitiello F, Morgillo F. Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?. Transl Cancer Res. 2019; 8:S618-20. DOI
  90. Mouronte-Roibas C, Leiro-Fernandez-Villa A, Botana-Rial M. COPD, emphysema and the onset of lung cancer. A systematic review. Cancer Lett. 2016; 382:240-4.
  91. Smith BM, Pinto L, Ezer N. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung Cancer. 2012; 77:58-63.
  92. Calabrò E, Randi G, La Vecchia C. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J. 2010; 35:146-51. DOI
  93. Mark NM, Kargl J, Busch SE. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am J Respir Crit Care Med. 2018; 197:325-36.
  94. Rizvi NA, Hellmann MD, Snyder A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124-8. DOI
  95. Perrotta F, Cennamo A, Cerqua FS. Effects of a high-intensity pulmonary rehabilitation program on the minute ventilation/carbon dioxide output slope during exercise in a cohort of patients with COPD undergoing lung resection for non-small cell lung cancer. J Bras Pneumol. 2019; 45:e20180132. DOI
  96. Salvi R, Meoli I, Cennamo A. Preoperative high-intensity training in frail old patients undergoing pulmonary resection for NSCLC. Open Med (Wars). 2016; 11:443-8. DOI
  97. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160:330-8.
  98. De Torres JP, Wilson DO, Sanchez-Salcedo P. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening score. Am J Resir Crit Care Med. 2015; 191:285-91.
  99. Young RP, Duan F, Chiles C. Airflow limitation and histologu shift in the National lung screening trial. The NLST-ACRIN Cohort Substudy. Am J Respir Crit Care Med. 2015; 192:1060-7.
  100. De Torres JP, Casanova C, Marin JM. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med. 2013; 107:702-7.
  101. Young RP, Hopkins RJ. Measures of outcome in lung cancer screening: maximising the benefits. J Thorac Dis. 2016; 8:e1317-20.
  102. Hudgel DW, Martin RJ, Johnson B. Mechanics of the respiratory system and breathing pattern during sleep in normal humans. J Appl Physiol Respir Environ Exerc Physiol. 1984; 56:133-7.
  103. Mollica M, Nicolai A, Maffucci R. Obstructive sleep apnea and cardiovascular risks in the elderly population. Journal of Gerontology and Geriatrics. 2018; 66:149-55.
  104. Collop N. Sleep and sleep disorders in chronic obstructive pulmonary disease. Respiration. 2010; 80:78-86.
  105. Lacedonia D, Nigro E, Matera MG. Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome. Pulm Pharmacol Ther. 2016; 40:104-8. DOI
  106. Machado MC, Vollmer WM, Togeiro SM. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J. 2010; 35:132-7. DOI
  107. Marin JM, Soriano JB, Carrizo SJ. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010; 182:325-31.
  108. Fletcher EC, Luckett RA, Goodnight-White S. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis. 1992; 145:1070-6.
  109. Patil SP, Ayappa IA, Caples SM. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019; 15:335-43.
  110. Cederholm T, Barazzoni R, Austin P. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017; 36:49-64. DOI
  111. Cruz-Jentoft AJ, Baeyens JP, Bauer JM. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010; 39:412-23. DOI
  112. Janssen I, Baumgartner RN, Ross R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004; 159:413-21.
  113. Ling CH, Taekema D, de Craen AJ. Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study. CMAJ. 2010; 182:429-35. DOI
  114. Kon SS, Patel MS, Canavan JL. Reliability and validity of 4-metre gait speed in COPD. Eur Respir J. 2013; 42:333-40. DOI
  115. De Blasio F, Di Gregorio A, De Blasio F. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respir Med. 2018; 134:1-5.
  116. De Blasio F, Scalfi L, Di Gregorio A. Raw bioelectrical impedance analysis variables are independent predictors of early all-cause mortality in patients with COPD. Chest. 2019; 155:1148-57. DOI
  117. De Blasio F, Santaniello MG, de Blasio F. Raw BIA variables are predictors of muscle strength in patients with chronic obstructive pulmonary disease. Eur J Clin Nutr. 2017; 71:1336-40. DOI
  118. De Blasio F, de Blasio F, Miracco Berlingieri G. Evaluation of body composition in COPD patients using multifrequency bioelectrical impedance analysis. Int J Chron Obstruct Pulmon Dis. 2016; 11:2419-26.
  119. Luo Y, Zhou L, Li Y. Fat-free mass index for evaluating the nutritional status and disease severity in COPD. Respir Care. 2016; 61:680-8. DOI
  120. Jones SE, Maddocks M, Kon SS. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015; 70:213-8. DOI
  121. Gan WQ, Man SF, Senthilselvan A. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59:574-80.
  122. Byun MK, Cho EN, Chang J. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12:669-75.
  123. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33:1165-85.
  124. Carbó N, Busquets S, van Royen M. TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. Br J Cancer. 2002; 86:1012-6.
  125. Takabatake N, Nakamura H, Abe S. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161:1179-84.
  126. De Theije C, Costes F, Langen RC. Hypoxia and muscle maintenance regulation: implications for chronic respiratory disease. Curr Opin Clin Nutr Metab Care. 2011; 14:548-53.
  127. Visser M, Schaap LA. Consequences of sarcopenia. Clin Geriatr Med. 2011; 27:387-99.
  128. Cruz-Jentoft AJ, Bahat G, Bauer J. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48:16-31.
  129. Ferreira IM, Brooks D, White J. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 12:Cd000998.
  130. Bauer J, Biolo G, Cederholm T. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013; 14:542-59.
  131. Kuchuk NO, Pluijm SM, van Schoor NM. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab. 2009; 94:1244-50.
  132. Molfino A, Gioia G, Rossi Fanelli F. Beta-hydroxy-beta-methylbutyrate supplementation in health and disease: a systematic review of randomized trials. Amino Acids. 2013; 45:1273-92.
  133. Corbi G, Conti V, Troisi J. Cardiac rehabilitation increases SIRT1 activity and β-hydroxybutyrate levels and decreases oxidative stress in patients with HF with preserved ejection fraction. Oxid Med Cell Longev. 2019; 2019:7049237. DOI
  134. Dalton JT, Taylor RP, Mohler ML. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013; 7:345-51.
  135. Graat-Verboom L, Wouters EF, Smeenk FW. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009; 34:209-18.
  136. Ohara T, Hirai T, Muro S. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest. 2008; 134:1244-9.
  137. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13:777-87.
  138. Walsh LJ, Wong CA, Oborne J. Adverse effect of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001; 56:279-84.
  139. Langhammer A, Forsmo S, Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone?. Int J Chron Obstruct Pulmon Dis. 2009; 4:365-80.
  140. Ferguson GT, Calverley PM, Anderson JA. Prevalence and progression of osteoporosis in patient with COPD: results from the TOwards a Revolution in COPD health study. Chest. 2009; 136:1456-65.
  141. Tang BM, Eslick GD, Nowson C. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007; 370:657-66.
  142. Smith BJ, Laslett LL, Pile KD. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis. 2004; 1:131-7.


Mariano Mollica

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Luigi Aronne

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Giorgio Paoli

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Martina Flora

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Grazia Mazzeo

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Stefania Tartaglione

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Rita Polito

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Naples, Italy

Carmelindo Tranfa

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Maria Ceparano

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Klara Komici

Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, Italy

Gennaro Mazzarella

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy

Carlo Iadevaia

Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”/Hosp. Monaldi, Naples, Italy


© Società Italiana di Gerontologia e Geriatria (SIGG) , 2020

How to Cite

Mollica, M., Aronne, L., Paoli, G., Flora, M., Mazzeo, G., Tartaglione, S., Polito, R., Tranfa, C., Ceparano, M., Komici, K., Mazzarella, G. and Iadevaia, C. 2020. Elderly with COPD: comoborbitidies and systemic consequences. JOURNAL OF GERONTOLOGY AND GERIATRICS. (Oct. 2020). DOI:
  • Abstract viewed - 70 times
  • PDF downloaded - 19 times